Form 4 for LQDA Liquidia Corp
Accepted 2026-05-15 18:59:31 ET · period of report 2026-05-13 · accession 0001104659-26-062852 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MTI | 2026-05-15 18:59 | 2026-05-13+ | LQDA | JEFFS ROGER | CEO, Dir | S - Sale | $57.32 | -75.0K | 1.20M | -6% | -$4.30M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-13 | S | D | 25,000 | $56.29 | 1,248,095 | I See footnote | — | — | (F3) Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. (F4) Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $53.99 to $57.77. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F5) The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |
| 2 | Common | Common Stock | 2026-05-14 | S | D | 25,000 | $58.62 | 1,223,095 | I See footnote | — | — | (F3) Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. (F6) Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.47 to $59.64. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F5) The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |
| 3 | Common | Common Stock | 2026-05-15 | S | D | 25,000 | $57.04 | 1,198,095 | I See footnote | — | — | (F3) Transaction effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on November 5, 2025. (F7) Price is the volume weighted average price of all transactions made by the Reporting Person on the transaction date for prices ranging from $56.18 to $58.60. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F5) The securities are held by Serendipity BioPharma LLC ("Serendipity"). The Reporting Person is a manager of Serendipity and has sole voting and dispositive power over the Issuer common stock held by Serendipity. |